• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

小儿肥厚型心肌病患者心肺运动试验的研究进展。

Insights from Cardiopulmonary Exercise Testing in Pediatric Patients with Hypertrophic Cardiomyopathy.

机构信息

Department of Clinical and Molecular Medicine, Sapienza University, 00189 Rome, Italy.

Paediatric Cardiology and ACHD Unit, S. Orsola, Malpighi Hospital, 40138 Bologna, Italy.

出版信息

Biomolecules. 2021 Mar 2;11(3):376. doi: 10.3390/biom11030376.

DOI:10.3390/biom11030376
PMID:33801562
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7999553/
Abstract

The usefulness of cardiopulmonary exercise test (CPET) in adult hypertrophic cardiomyopathy (HCM) patients is well-known, whereas its role in pediatric HCM patients has not yet been explored. The present study investigates possible insights from a CPET assessment in a cohort of pediatric HCM outpatients in terms of functional and prognostic assessment. Sixty consecutive pediatric HCM outpatients aged <18 years old were enrolled, each of them undergoing a full clinical assessment including a CPET; a group of 60 healthy subjects served as controls. A unique composite end-point of heart failure (HF) related and sudden cardiac death (SCD) or SCD-equivalent events was also explored. During a median follow-up of 53 months (25th-75th: 13-84 months), a total of 13 HF- and 7 SCD-related first events were collected. Compared to controls, HCM patients showed an impaired functional capacity with most of them showing peak oxygen uptake (pVO) values of <80% of the predicted, clearly discrepant with functional New York Heart Association class assessment. The composite end-point occurred more frequently in patients with the worst CPETs' profiles. At the univariate analysis, pVO% was the variable with the strongest association with adverse events at follow-up (C-index = 0.72, = 0.025) and a cut-off value equal to 60% was the most accurate in identifying those patients at the highest risk. In a pediatric HCM subset, the CPET assessment allows a true functional capacity estimation and it might be helpful in identifying early those patients at high risk of events.

摘要

心肺运动试验(CPET)在成人肥厚型心肌病(HCM)患者中的应用价值已得到广泛认可,但其在儿科 HCM 患者中的作用尚未得到充分探索。本研究旨在探讨 CPET 评估在儿科 HCM 门诊患者中的功能和预后评估方面可能具有的作用。

连续纳入 60 例年龄<18 岁的儿科 HCM 门诊患者,每位患者均接受全面的临床评估,包括 CPET;同时纳入 60 例健康对照者。还探索了心力衰竭(HF)相关和心源性猝死(SCD)或 SCD 等效事件的独特复合终点。

在中位随访 53 个月(25-75%:13-84 个月)期间,共收集到 13 例 HF 相关和 7 例 SCD 相关的首发事件。与对照组相比,HCM 患者的功能能力受损,其中大多数患者的峰值摄氧量(pVO)值<预测值的 80%,与纽约心脏协会(NYHA)功能分级明显不符。复合终点在 CPET 结果最差的患者中更常见。

在单因素分析中,pVO%是与随访时不良事件相关性最强的变量(C 指数=0.72,p=0.025),60%的截断值是识别风险最高患者的最准确值。在儿科 HCM 亚组中,CPET 评估可准确评估患者的实际功能能力,有助于早期识别高风险患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6467/7999553/f6faf947118b/biomolecules-11-00376-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6467/7999553/6d5724ee1c86/biomolecules-11-00376-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6467/7999553/48f84d671cb6/biomolecules-11-00376-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6467/7999553/f6faf947118b/biomolecules-11-00376-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6467/7999553/6d5724ee1c86/biomolecules-11-00376-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6467/7999553/48f84d671cb6/biomolecules-11-00376-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6467/7999553/f6faf947118b/biomolecules-11-00376-g003.jpg

相似文献

1
Insights from Cardiopulmonary Exercise Testing in Pediatric Patients with Hypertrophic Cardiomyopathy.小儿肥厚型心肌病患者心肺运动试验的研究进展。
Biomolecules. 2021 Mar 2;11(3):376. doi: 10.3390/biom11030376.
2
Clinical and prognostic impact of chronotropic incompetence in patients with hypertrophic cardiomyopathy.肥厚型心肌病患者变时性功能不全的临床和预后影响。
Int J Cardiol. 2018 Nov 15;271:125-131. doi: 10.1016/j.ijcard.2018.04.019. Epub 2018 Aug 4.
3
Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH Trial.早期和亚临床肥厚型心肌病的生活质量和运动能力:VANISH 试验的二次分析。
Circ Heart Fail. 2024 Aug;17(8):e011663. doi: 10.1161/CIRCHEARTFAILURE.124.011663. Epub 2024 Aug 1.
4
Cardiopulmonary responses and prognosis in hypertrophic cardiomyopathy: a potential role for comprehensive noninvasive hemodynamic assessment.肥厚型心肌病的心肺反应和预后:全面无创血液动力学评估的潜在作用。
JACC Heart Fail. 2015 May;3(5):408-418. doi: 10.1016/j.jchf.2014.11.011. Epub 2015 Apr 8.
5
The impact of cardiopulmonary exercise-derived scoring on prediction of cardio-cerebral outcome in hypertrophic cardiomyopathy.心肺运动衍生评分对肥厚型心肌病心脑血管结局预测的影响。
PLoS One. 2022 Jan 14;17(1):e0259638. doi: 10.1371/journal.pone.0259638. eCollection 2022.
6
Cardiopulmonary exercise test and sudden cardiac death risk in hypertrophic cardiomyopathy.肥厚型心肌病患者的心肺运动试验与心源性猝死风险
Heart. 2016 Apr;102(8):602-9. doi: 10.1136/heartjnl-2015-308453. Epub 2016 Feb 5.
7
Heart Failure Progression in Hypertrophic Cardiomyopathy - Possible Insights From Cardiopulmonary Exercise Testing.肥厚型心肌病中心力衰竭的进展——心肺运动试验的潜在见解
Circ J. 2016 Sep 23;80(10):2204-11. doi: 10.1253/circj.CJ-16-0432. Epub 2016 Sep 13.
8
The prognostic value of peak oxygen uptake in obstructive hypertrophic cardiomyopathy: a literature review to inform economic model development.峰值摄氧量在梗阻性肥厚型心肌病中的预后价值:文献综述以支持经济模型的开发。
J Med Econ. 2024 Jan-Dec;27(1):817-825. doi: 10.1080/13696998.2024.2367920. Epub 2024 Jul 1.
9
Determinants of peak oxygen uptake in patients with hypertrophic cardiomyopathy: a single-center study.肥厚型心肌病患者峰值摄氧量的决定因素:一项单中心研究。
Intern Emerg Med. 2014 Apr;9(3):293-302. doi: 10.1007/s11739-012-0866-x. Epub 2012 Oct 7.
10
Exercise oxygen pulse kinetics in patients with hypertrophic cardiomyopathy.肥厚型心肌病患者的运动氧脉搏动力学。
Heart. 2022 Sep 26;108(20):1629-1636. doi: 10.1136/heartjnl-2021-320569.

引用本文的文献

1
Serial Exercise Testing in Children With Known or Suspected Congenital and Acquired Heart Disease: A Narrative Review and Survey of Current Practice.已知或疑似患有先天性和后天性心脏病儿童的系列运动测试:叙述性综述及当前实践调查
J Am Heart Assoc. 2025 Apr 15;14(8):e038585. doi: 10.1161/JAHA.124.038585. Epub 2025 Apr 10.
2
Brazilian Guideline for Exercise Testing in Children and Adolescents - 2024.巴西儿童和青少年运动测试指南-2024 年版。
Arq Bras Cardiol. 2024 Sep 16;121(8):e20240525. doi: 10.36660/abc.20240525.
3
Collagen protein-chitosan nerve conduits with neuroepithelial stem cells promote peripheral nerve regeneration.

本文引用的文献

1
Prescribing, dosing and titrating exercise in patients with hypertrophic cardiomyopathy for prevention of comorbidities: Ready for prime time.为预防合并症为肥厚型心肌病患者开具运动处方、确定剂量并进行调整:准备好进入黄金时期。
Eur J Prev Cardiol. 2021 Aug 23;28(10):1093-1099. doi: 10.1177/2047487320928654.
2
Characteristics and Longer-Term Outcomes of Contemporary Patients <18 Years of Age With Hypertrophic Cardiomyopathy.当代 <18 岁肥厚型心肌病患者的特征和长期预后。
Am J Cardiol. 2021 Feb 1;140:110-117. doi: 10.1016/j.amjcard.2020.10.060. Epub 2020 Nov 4.
3
Exercise in hypertrophic cardiomyopathy: towards a personalised approach.
胶原蛋白-壳聚糖神经导管联合神经上皮干细胞促进周围神经再生。
Sci Rep. 2024 Sep 5;14(1):20748. doi: 10.1038/s41598-024-71435-x.
4
Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH Trial.早期和亚临床肥厚型心肌病的生活质量和运动能力:VANISH 试验的二次分析。
Circ Heart Fail. 2024 Aug;17(8):e011663. doi: 10.1161/CIRCHEARTFAILURE.124.011663. Epub 2024 Aug 1.
5
Cardiopulmonary Exercise Testing in Children and Young Adolescents after a Multisystem Inflammatory Syndrome: Physical Deconditioning or Residual Pathology?多系统炎症综合征后儿童和青少年的心肺运动测试:身体失健还是残留病理状态?
J Clin Med. 2023 Mar 19;12(6):2375. doi: 10.3390/jcm12062375.
6
The Prevalence and Association of Exercise Test Abnormalities With Sudden Cardiac Death and Transplant-Free Survival in Childhood Hypertrophic Cardiomyopathy.运动试验异常与儿童肥厚型心肌病猝死和无移植生存的相关性及患病率。
Circulation. 2023 Feb 28;147(9):718-727. doi: 10.1161/CIRCULATIONAHA.122.062699. Epub 2022 Nov 6.
7
Family screening of hypertrophic cardiomyopathy in children: a case report.儿童肥厚型心肌病的家族筛查:一例报告
Eur Heart J Case Rep. 2022 Sep 3;6(9):ytac360. doi: 10.1093/ehjcr/ytac360. eCollection 2022 Sep.
肥厚型心肌病的运动:迈向个性化治疗方案
Eur J Prev Cardiol. 2021 Aug 23;28(10):1091-1092. doi: 10.1177/2047487320957792.
4
Prediction and Prevention of Sudden Death in Young Patients (<20 years) With Hypertrophic Cardiomyopathy.肥厚型心肌病年轻患者(<20 岁)猝死的预测和预防。
Am J Cardiol. 2020 Aug 1;128:75-83. doi: 10.1016/j.amjcard.2020.04.042. Epub 2020 May 13.
5
Risk Stratification in Hypertrophic Cardiomyopathy. Insights from Genetic Analysis and Cardiopulmonary Exercise Testing.肥厚型心肌病的风险分层。来自基因分析和心肺运动试验的见解。
J Clin Med. 2020 May 28;9(6):1636. doi: 10.3390/jcm9061636.
6
Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids).儿童肥厚型心肌病(HCM Risk-Kids)中发生心源性猝死的新型风险预测模型的建立。
JAMA Cardiol. 2019 Sep 1;4(9):918-927. doi: 10.1001/jamacardio.2019.2861.
7
Risk Prediction Model in Children With Hypertrophic Cardiomyopathy: A Work in Progress.肥厚型心肌病患儿的风险预测模型:一项正在进行的工作。
JAMA Cardiol. 2019 Sep 1;4(9):927. doi: 10.1001/jamacardio.2019.2945.
8
Cardiomyopathy in Children: Classification and Diagnosis: A Scientific Statement From the American Heart Association.儿童心肌病:分类与诊断——美国心脏协会科学声明
Circulation. 2019 Jul 2;140(1):e9-e68. doi: 10.1161/CIR.0000000000000682. Epub 2019 May 28.
9
Clinical presentation and survival of childhood hypertrophic cardiomyopathy: a retrospective study in United Kingdom.英国一项儿童肥厚型心肌病的临床特征和生存情况的回顾性研究。
Eur Heart J. 2019 Mar 21;40(12):986-993. doi: 10.1093/eurheartj/ehy798.
10
Peak oxygen uptake in heart failure: Look behind the number!心力衰竭中的峰值摄氧量:透过数字看本质!
Eur J Prev Cardiol. 2018 Dec;25(18):1934-1936. doi: 10.1177/2047487318806987. Epub 2018 Oct 22.